Characterization of human DNA topoisomerase II as an autoantigen recognized by patients with IDDM

Yih Hsin Chang, Jaulang Hwang, Huey Fang Shang, Shih Tzer Tsai

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Autoantibodies against several cytoplasmic autoantigens such as glutamic acid decarboxylase, heat shock protein 65, insulin, and carboxypeptidase H have been identified in the sera of patients with IDDM. To investigate whether type II DNA topoisomerase (TopII) is an autoantigen in IDDM patients, we have constructed a series of overlapping DNA TopII fragments that covered the entire length of this enzyme. These fragments were used as antigens to screen sera of IDDM patients. We have examined 195 Chinese IDDM patients (mean age 14.2 ± 7.5 years, age at onset 9.2 ± 6.4 years, duration of diabetes 4.6 ± 3.4 years) and 51 nondiabetic individuals. The results showed that DNA TopII autoantibodies were detected in 49.2 and 47.2% of IDDM patients using purified TopII fragments and full-length TopII as antigens, respectively. The frequency of anti-TopII positivity was relatively stable irrespective of sex and disease duration. The patients were slightly older at onset and the prevalence of anti-thyroglobulin/anti-microsomal autoantibodies was twice that in the IDDM subgroup positive for anti-TopII than in IDDM patients who were negative for anti-TopII. We also characterized the epitopes of DNA TopII that were recognized by IDDM sera. Those epitopes resided mostly in three distinct domains. One resided in amino acid residues 1-147, another in amino acid residues 286-472, and the third in the COOH-terminal one-third of DNA TopII. Intriguingly, we found that these epitopes shared similarity (up to 36% identity and 63.6% homology) to previously identified epitopes of IDDM autoantigens.

Original languageEnglish
Pages (from-to)408-414
Number of pages7
JournalDiabetes
Volume45
Issue number4
Publication statusPublished - Apr 1996
Externally publishedYes

Fingerprint

Type II DNA Topoisomerase
Autoantigens
Type 1 Diabetes Mellitus
Epitopes
Autoantibodies
DNA
Carboxypeptidase H
Serum
Antigens
Amino Acids
Glutamate Decarboxylase
Heat-Shock Proteins
Age of Onset
Insulin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Chang, Y. H., Hwang, J., Shang, H. F., & Tsai, S. T. (1996). Characterization of human DNA topoisomerase II as an autoantigen recognized by patients with IDDM. Diabetes, 45(4), 408-414.

Characterization of human DNA topoisomerase II as an autoantigen recognized by patients with IDDM. / Chang, Yih Hsin; Hwang, Jaulang; Shang, Huey Fang; Tsai, Shih Tzer.

In: Diabetes, Vol. 45, No. 4, 04.1996, p. 408-414.

Research output: Contribution to journalArticle

Chang, YH, Hwang, J, Shang, HF & Tsai, ST 1996, 'Characterization of human DNA topoisomerase II as an autoantigen recognized by patients with IDDM', Diabetes, vol. 45, no. 4, pp. 408-414.
Chang, Yih Hsin ; Hwang, Jaulang ; Shang, Huey Fang ; Tsai, Shih Tzer. / Characterization of human DNA topoisomerase II as an autoantigen recognized by patients with IDDM. In: Diabetes. 1996 ; Vol. 45, No. 4. pp. 408-414.
@article{c1deca11417c45d693df540abab61ec8,
title = "Characterization of human DNA topoisomerase II as an autoantigen recognized by patients with IDDM",
abstract = "Autoantibodies against several cytoplasmic autoantigens such as glutamic acid decarboxylase, heat shock protein 65, insulin, and carboxypeptidase H have been identified in the sera of patients with IDDM. To investigate whether type II DNA topoisomerase (TopII) is an autoantigen in IDDM patients, we have constructed a series of overlapping DNA TopII fragments that covered the entire length of this enzyme. These fragments were used as antigens to screen sera of IDDM patients. We have examined 195 Chinese IDDM patients (mean age 14.2 ± 7.5 years, age at onset 9.2 ± 6.4 years, duration of diabetes 4.6 ± 3.4 years) and 51 nondiabetic individuals. The results showed that DNA TopII autoantibodies were detected in 49.2 and 47.2{\%} of IDDM patients using purified TopII fragments and full-length TopII as antigens, respectively. The frequency of anti-TopII positivity was relatively stable irrespective of sex and disease duration. The patients were slightly older at onset and the prevalence of anti-thyroglobulin/anti-microsomal autoantibodies was twice that in the IDDM subgroup positive for anti-TopII than in IDDM patients who were negative for anti-TopII. We also characterized the epitopes of DNA TopII that were recognized by IDDM sera. Those epitopes resided mostly in three distinct domains. One resided in amino acid residues 1-147, another in amino acid residues 286-472, and the third in the COOH-terminal one-third of DNA TopII. Intriguingly, we found that these epitopes shared similarity (up to 36{\%} identity and 63.6{\%} homology) to previously identified epitopes of IDDM autoantigens.",
author = "Chang, {Yih Hsin} and Jaulang Hwang and Shang, {Huey Fang} and Tsai, {Shih Tzer}",
year = "1996",
month = "4",
language = "English",
volume = "45",
pages = "408--414",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "4",

}

TY - JOUR

T1 - Characterization of human DNA topoisomerase II as an autoantigen recognized by patients with IDDM

AU - Chang, Yih Hsin

AU - Hwang, Jaulang

AU - Shang, Huey Fang

AU - Tsai, Shih Tzer

PY - 1996/4

Y1 - 1996/4

N2 - Autoantibodies against several cytoplasmic autoantigens such as glutamic acid decarboxylase, heat shock protein 65, insulin, and carboxypeptidase H have been identified in the sera of patients with IDDM. To investigate whether type II DNA topoisomerase (TopII) is an autoantigen in IDDM patients, we have constructed a series of overlapping DNA TopII fragments that covered the entire length of this enzyme. These fragments were used as antigens to screen sera of IDDM patients. We have examined 195 Chinese IDDM patients (mean age 14.2 ± 7.5 years, age at onset 9.2 ± 6.4 years, duration of diabetes 4.6 ± 3.4 years) and 51 nondiabetic individuals. The results showed that DNA TopII autoantibodies were detected in 49.2 and 47.2% of IDDM patients using purified TopII fragments and full-length TopII as antigens, respectively. The frequency of anti-TopII positivity was relatively stable irrespective of sex and disease duration. The patients were slightly older at onset and the prevalence of anti-thyroglobulin/anti-microsomal autoantibodies was twice that in the IDDM subgroup positive for anti-TopII than in IDDM patients who were negative for anti-TopII. We also characterized the epitopes of DNA TopII that were recognized by IDDM sera. Those epitopes resided mostly in three distinct domains. One resided in amino acid residues 1-147, another in amino acid residues 286-472, and the third in the COOH-terminal one-third of DNA TopII. Intriguingly, we found that these epitopes shared similarity (up to 36% identity and 63.6% homology) to previously identified epitopes of IDDM autoantigens.

AB - Autoantibodies against several cytoplasmic autoantigens such as glutamic acid decarboxylase, heat shock protein 65, insulin, and carboxypeptidase H have been identified in the sera of patients with IDDM. To investigate whether type II DNA topoisomerase (TopII) is an autoantigen in IDDM patients, we have constructed a series of overlapping DNA TopII fragments that covered the entire length of this enzyme. These fragments were used as antigens to screen sera of IDDM patients. We have examined 195 Chinese IDDM patients (mean age 14.2 ± 7.5 years, age at onset 9.2 ± 6.4 years, duration of diabetes 4.6 ± 3.4 years) and 51 nondiabetic individuals. The results showed that DNA TopII autoantibodies were detected in 49.2 and 47.2% of IDDM patients using purified TopII fragments and full-length TopII as antigens, respectively. The frequency of anti-TopII positivity was relatively stable irrespective of sex and disease duration. The patients were slightly older at onset and the prevalence of anti-thyroglobulin/anti-microsomal autoantibodies was twice that in the IDDM subgroup positive for anti-TopII than in IDDM patients who were negative for anti-TopII. We also characterized the epitopes of DNA TopII that were recognized by IDDM sera. Those epitopes resided mostly in three distinct domains. One resided in amino acid residues 1-147, another in amino acid residues 286-472, and the third in the COOH-terminal one-third of DNA TopII. Intriguingly, we found that these epitopes shared similarity (up to 36% identity and 63.6% homology) to previously identified epitopes of IDDM autoantigens.

UR - http://www.scopus.com/inward/record.url?scp=0029914499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029914499&partnerID=8YFLogxK

M3 - Article

C2 - 8603760

AN - SCOPUS:0029914499

VL - 45

SP - 408

EP - 414

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 4

ER -